Literature DB >> 26045992

Inhibition of Aurora A promotes chemosensitivity via inducing cell cycle arrest and apoptosis in cervical cancer cells.

Jian-Ming Sun1, Li-Na Yang2, Han Xu3, Bin Chang4, Hua-Ying Wang5, Gong Yang6.   

Abstract

Aurora kinase A (AurA) regulates genomic instability and tumorigenesis in multiple cancer types. Although some studies have reported that Aur A may predict cervical cancer outcomes, its precise function and molecular mechanism in cervical cancer pathogenesis remain unclear. In this study, by overexpression or silencing of Aur A in cervical cancer cell lines, we found that overexpression of Aur A promoted cell proliferation through G1/S cell cycle transition and anti-apoptosis, xenograft tumor growth and chemoresistance to Taxol. We further found that inhibition of Aur A with its specific inhibitor VX-680 enhanced the antitumor effect of Taxol via inducing apoptosis. Moreover, the clinical analysis from tissue samples demonstrated that Aur A was overexpressed, and the expression of Aur A and pERK1/2 was negatively correlated in cervical cancer tissues. The above results may provide some potential insights in treatment of cervical cancer in clinic.

Entities:  

Keywords:  Aurora A; Taxol; VX-680; cervical cancer; chemoresistance

Year:  2015        PMID: 26045992      PMCID: PMC4449441     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  41 in total

1.  Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2.

Authors:  Gong Yang; Bin Chang; Fan Yang; Xiaoqing Guo; Kathy Qi Cai; Xue Sherry Xiao; Huamin Wang; Subrata Sen; Mien-Chie Hung; Gordon B Mills; Sandy Chang; Asha S Multani; Imelda Mercado-Uribe; Jinsong Liu
Journal:  Clin Cancer Res       Date:  2010-04-27       Impact factor: 12.531

Review 2.  A death-promoting role for extracellular signal-regulated kinase.

Authors:  Shougang Zhuang; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2006-06-26       Impact factor: 4.030

Review 3.  ERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence.

Authors:  Sebastien Cagnol; Jean-Claude Chambard
Journal:  FEBS J       Date:  2009-10-16       Impact factor: 5.542

4.  Stanniocalcin 1 and ovarian tumorigenesis.

Authors:  Guangzhi Liu; Gong Yang; Bin Chang; Imelda Mercado-Uribe; Miao Huang; Jingfang Zheng; Robert C Bast; Sue-Hwa Lin; Jinsong Liu
Journal:  J Natl Cancer Inst       Date:  2010-05-18       Impact factor: 13.506

5.  Expression of Aurora kinase A and B in normal and malignant cervical tissue: high Aurora A kinase expression in squamous cervical cancer.

Authors:  Nae-Fang Twu; Chiou-Chung Yuan; Ming-Shyen Yen; Chiung-Ru Lai; Kuan-Chong Chao; Peng-Hui Wang; Hua-Hsi Wu; Yi-Jen Chen
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2008-12-06       Impact factor: 2.435

6.  Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma.

Authors:  Abhijit Mazumdar; Ying C Henderson; Adel K El-Naggar; Subrata Sen; Gary L Clayman
Journal:  Head Neck       Date:  2009-05       Impact factor: 3.147

7.  Correlation between Aurora-A expression and the prognosis of cervical carcinoma patients.

Authors:  Wei Zhang; Jian Wang; Shu-Juan Liu; Wei Hua; Xiao-Yan Xin
Journal:  Acta Obstet Gynecol Scand       Date:  2009       Impact factor: 3.636

8.  Targeting Aurora kinases for the treatment of prostate cancer.

Authors:  Edmund Chun Yu Lee; Anna Frolov; Rile Li; Gustavo Ayala; Norman M Greenberg
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

9.  Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia.

Authors:  Xue-Fei Huang; Shao-Kai Luo; Jie Xu; Juan Li; Duo-Rong Xu; Li-Hui Wang; Min Yan; Xian-Ren Wang; Xiang-Bo Wan; Fei-Meng Zheng; Yi-Xin Zeng; Quentin Liu
Journal:  Blood       Date:  2007-12-26       Impact factor: 22.113

10.  Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells.

Authors:  Christopher D Scharer; Noelani Laycock; Adeboye O Osunkoya; Sanjay Logani; John F McDonald; Benedict B Benigno; Carlos S Moreno
Journal:  J Transl Med       Date:  2008-12-11       Impact factor: 5.531

View more
  14 in total

1.  Investigation of differentially-expressed microRNAs and genes in cervical cancer using an integrated bioinformatics analysis.

Authors:  Zhanzhan Xu; Yu Zhou; Fang Shi; Yexuan Cao; Thi Lan Anh Dinh; Jing Wan; Min Zhao
Journal:  Oncol Lett       Date:  2017-02-22       Impact factor: 2.967

2.  The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer.

Authors:  Xin Jin; Qingqing Mo; Yu Zhang; Yue Gao; Yuan Wu; Jing Li; Xing Hao; Ding Ma; Qinglei Gao; Pingbo Chen
Journal:  Cancer Biol Ther       Date:  2016-05-03       Impact factor: 4.742

3.  The impact of Aurora kinase A genetic polymorphisms on cervical cancer progression and clinicopathologic characteristics.

Authors:  Pei-Ju Wu; Chun-Hao Wang; Ming-Hong Hsieh; Chung-Yuan Lee; Po-Hui Wang; Chiao-Wen Lin; Shun-Fa Yang; Maw-Sheng Lee
Journal:  Int J Med Sci       Date:  2021-04-22       Impact factor: 3.738

Review 4.  Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine.

Authors:  Stephen Murata; Catherine Zhang; Nathan Finch; Kevin Zhang; Loredana Campo; Eun-Kyoung Breuer
Journal:  Biomed Res Int       Date:  2016-08-24       Impact factor: 3.411

5.  RNA interference in head and neck oncology.

Authors:  Agnieszka Sobecka; Wojciech Barczak; Wiktoria Maria Suchorska
Journal:  Oncol Lett       Date:  2016-09-02       Impact factor: 2.967

6.  Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.

Authors:  Huifeng Niu; Hyunjin Shin; Feng Gao; Jacob Zhang; Brittany Bahamon; Hadi Danaee; Bohuslav Melichar; Russell J Schilder; Robert L Coleman; Gerald Falchook; Antoine Adenis; Kian Behbakht; Angela DeMichele; Elizabeth Claire Dees; Kimberly Perez; Ursula Matulonis; Piotr Sawrycki; Dirk Huebner; Jeffrey Ecsedy
Journal:  EBioMedicine       Date:  2017-10-16       Impact factor: 8.143

7.  Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells.

Authors:  Mateusz Opyrchal; Malgorzata Gil; Jeffrey L Salisbury; Mathew P Goetz; Vera Suman; Amy Degnim; James McCubrey; Tufia Haddad; Ianko Iankov; Chenye B Kurokawa; Nicole Shumacher; James N Ingle; Evanthia Galanis; Antonino B D'Assoro
Journal:  Oncotarget       Date:  2017-09-01

8.  Inhibition of Aurora Kinase A by Alisertib Reduces Cell Proliferation and Induces Apoptosis and Autophagy in HuH-6 Human Hepatoblastoma Cells.

Authors:  Jingyi Tan; Wenfeng Xu; Lei Lei; Hui Liu; Hong Wang; Xian Cao; Man Xu
Journal:  Onco Targets Ther       Date:  2020-05-08       Impact factor: 4.147

9.  Identification of key genes and pathways of diagnosis and prognosis in cervical cancer by bioinformatics analysis.

Authors:  Hua-Ju Yang; Jin-Min Xue; Jie Li; Ling-Hong Wan; Yu-Xi Zhu
Journal:  Mol Genet Genomic Med       Date:  2020-03-17       Impact factor: 2.183

10.  Potential new biomarkers for squamous carcinoma of the uterine cervix.

Authors:  Peter A van Dam; Christian Rolfo; Rossana Ruiz; Patrick Pauwels; Christophe Van Berckelaer; Xuan Bich Trinh; Jose Ferri Gandia; Johannes P Bogers; Steven Van Laere
Journal:  ESMO Open       Date:  2018-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.